Literature DB >> 12210712

In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy.

J Muncunill1, P Vaquer, A Galmés, A Obrador, M Parera, J Bargay, J Besalduch.   

Abstract

The current treatment of hereditary hemochromatosis (HH) consists of performing periodic manual whole blood phlebotomies. Erythroapheresis (EPH) is considered to be an alternative procedure if the classic treatment is contra-indicated. A prospective study of 13 consecutive cases of HH were included in a periodic EPH program with the aim of assessing the efficacy, feasibility, and tolerability of EPH in the treatment of HH by induction and maintenance. Iron depletion (ferritin <20 microg/l) was achieved in all patients after a mean of 6.7 +/- 2.9 months of treatment and a mean of 13.5 +/- 7.2 EPH sessions. The procedure was well tolerated and there were no complications. After a follow-up period of 10.5 +/- 6.6 months, only four patients have required further maintenance sessions beyond 6 months after completing the induction therapy. The efficacy, speed, tolerability, and more favorable schedule of an EPH program facilitate treatment of HH. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210712     DOI: 10.1002/jca.10024

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  3 in total

1.  Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.

Authors:  Tatjana Sundic; Tor Hervig; Signe Hannisdal; Jörg Assmus; Rune J Ulvik; Richard W Olaussen; Sigbjørn Berentsen
Journal:  Blood Transfus       Date:  2013-10-23       Impact factor: 3.443

2.  Management of cardiac hemochromatosis.

Authors:  Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2017-06-30       Impact factor: 3.318

3.  A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.

Authors:  Eva Rombout-Sestrienkova; Bjorn Winkens; Marian van Kraaij; Cees Th B M van Deursen; Mirian C H Janssen; Alexander M J Rennings; Dorothea Evers; Jean-Louis Kerkhoffs; Ad Masclee; Ger H Koek
Journal:  J Clin Apher       Date:  2020-12-24       Impact factor: 2.821

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.